http://www.thedailystar.

net/supplements/24th-anniversary-the-daily-star-part-1/newparadigm-global-generic-medicines-73290

Bangladesh has all the potentials to become a new paradigm for global generic
medicines. With a population of 156.66 million, the country's social development
indicators are very promising. Bangladesh is enjoying a consistent GDP growth of more
than 6 percent over the last 10 years. Commendable progress has been made in areas
like annual GDP growth, per capita GDP, population growth, literacy rate etc. The
country's balance of payment (export plus foreign remittance minus import) is
consistently increasing. Renowned global investment analysts like JP Morgan, Goldman
Sachs, Investors Chronicle have highly rated Bangladesh as an attractive investment
destination. Outgoing US Ambassador to Bangladesh Dan W Mozena specially focused
on the potential of pharmaceutical sector along with the RMG, leather, IT sectors. He
said that the Bangladeshi pharmaceutical companies will have a huge market in the
USA. Bangladeshi pharmaceutical companies are in the process of getting approval from
the US-FDA.
Within two to three decades the Pharmaceutical sector has made a complete
turnaround from an import dependent industry to almost self-sufficiency. There are
about 270 licensed pharmaceutical manufacturers in the country of which over 198
companies are in operation. Domestic manufacture accounts for 97percent of the drug
sales in the local market while the remaining three percent is imported. Pharma sector
is now considered technologically the most developed manufacturing industrial sector in
Bangladesh and the second highest contributor to the national exchequer. The local
market is about USD 1.51 billion and is the largest white collar employment sector.
Pharma exports have risen to around USD 59.82 million in fiscal 2012-13 with CAGR of
25.5 percent for the last five years. There is a growing demand for Bangladeshi
medicines in Southeast Asia, Asia Pacific and Africa. At present around 30 Bangladeshi
pharmaceutical companies are exporting medicines to 90 countries in Europe, Asia,
Africa and Latin America. Bangladeshi companies are now focusing on developed
markets such as Europe, Australia, Latin America and the Gulf countries. Top companies

have already started exporting to stringently regulated markets and are getting very
good responses.
In the next couple of years, the Bangladesh pharma industry will grow stronger and play
a major role in the global generic market which is now USD 300 Billion with a CAGR of
9.3 percent. Within 2017, there will be patent expiry of some blockbuster drugs and as a
result the global generic market will be more than USD 400 billion. Around 80 percent of
the world's population consumes generic products. Moreover, in many countries, new
government provisions, changing demographics and the lifestyle will continue to
increase the use of global generic medicines. India and China are the major players in
the world generic market.
According to industry experts, most of the developed countries are looking for another
dependable alternative source rather than India and China and this is where Bangladesh
can strongly position itself as the most suitable and competitive candidate to capture
substantial market share of global generic medicine. As a result, Bangladesh can
emerge as a potential global generic player.
With this objective in mind, in the last couple of years, Bangladeshi pharmaceuticals
companies made huge investments (more than USD 500 million) for facility expansion
and product development. The country is now capable of producing high-tech biosimilar
products such as erythropoietin, enoxaparin, insulin, etc. and sterile products like LVP
and SVP, prefilled syringe, freeze-dried products, MDI (Metered Dose Inhaler), hormone
and steroid products in their state-of-the-art manufacturing facilities. The country has a
large pool of highly-skilled human resource both at home and abroad who are capable
to transform Bangladesh to a major global source of affordable generic medicines and
vaccines. By this time, a good number of pharmaceutical companies have obtained
certifications from the UK, the European Union, Australia, the Gulf countries and other
regulatory authorities. Within a couple of years, more Bangladeshi companies will
receive certification from these authorities. At present 3,600 Bangladeshi brands are
already internationally registered and among them 100 are in regulated markets.
For contract manufacturing, merger and acquisition in respect to pharmaceutical
formulations, Bangladesh is definitely an attractive destination. Bangladesh now has
world class pharmaceutical production facilities along with low overhead and other
related cost compared to other major cities like Shanghai, New Delhi and Seoul. The
details below show a clearer picture:
There are still a few challenges ahead. API development capabilities and know-how is a
must for being a competent global generic manufacturer. Bangladeshi companies are
almost dependent on RM import from foreign countries, thus incurring higher cost of its
production. The country also needs to develop own CROs like Bio-equivalence (BE)
testing facilities both is the government and private sectors.
It is very encouraging that the Bangladesh government has declared the pharma
industry as a thrust sector. It has allocated land for API park development and initiative
has been taken for setting up a modern drug testing laboratory in association with the
Bangladesh Association of Pharmaceutical Industry (BAPI). The present government is
also serious about removing all bottle necks from pharma export. So, with world class
production facilities and international certifications coupled with cost and TRIPS
agreement, the advantages are already there.

..................................................................
The writer is Managing Director, Novelta Bestway Pharmaceuticals Ltd.

HTTP://WWW.THEDAILYSTAR.NET/MIDDLE-EASTERN-DRUG-MAKERBUYS-OUT-RAK-PHARMA-56650
MIDDLE-EASTERN DRUG MAKER BUYS OUT RAK PHARMA

Middle-Eastern drug maker

buys out RAK Pharma
Star Business Report

Middle-Eastern drug manufacturer Julphar and its partners will acquire a 77.5 percent stake in Dhaka-based
RAK Pharmaceuticals.
UAE-based Julphar will bear some liabilities of RAK Pharmaceuticals, with 55 percent of its shares owned by
RAK Ceramics, a listed company in Bangladesh.
Julphar will invest around Tk 75 crore ($9.5 million) to acquire the shares and settle the liabilities, RAK
Ceramics said in a posting on the Dhaka Stock Exchange website yesterday.

RAK Ceramics will transfer its entire holding of 5.17 crore ordinary shares of RAK Pharmaceuticals to Julphar
for Tk 7 each share -- all amounting to Tk 36.19 crore.
An independent value assessor determined the transfer value, RAK Ceramics said, adding that the matter has
been approved by the company's board of directors. RAK Ceramics, a Bangladesh-UAE joint venture, was
listed on the stockmarket in 2010. Each share of the tiles and sanitary-ware manufacturer traded between Tk
60.1 and Tk 60.9, before closing at Tk 64.9 yesterday.
The company's net profit fell 11.53 percent year-on-year to Tk 42.48 crore in January-September, with Tk 1.26
in earnings per share compared to Tk 1.43 a year ago.

https://www.bd.com/press-details/18805/Becton-Dickinson-Completes-Acquisition-of-CareFusion

NEWS & EVENTS

Becton Dickinson Completes Acquisition of CareFusion

Contact: Monique N. Dolecki

Investor Relations
(201) 847-5378
Email: monique_dolecki@bd.com
Kristen Cardillo
Media
(858) 617-2317
Email: kristen.cardillo@carefusion.com

Franklin Lakes, NJ (March 17, 2015)

Becton, Dickinson and Company (NYSE: BDX) ("BD") today announced that it
completed its acquisition of CareFusion Corporation ("CareFusion") pursuant to the
terms of its previously announced Agreement and Plan of Merger, dated October 5,
2014 (the Merger Agreement).
Vincent A. Forlenza, BDs Chairman, Chief Executive Officer and President, said, We
are very excited to announce the consummation of the CareFusion acquisition, as it
represents a major milestone in BDs 118-year history. This acquisition significantly
accelerates BDs strategy and builds scale and depth in medication management and
patient safety solutions. We look forward to the future with confidence as we become
one of the largest global leaders in medical technology, and are better positioned to

partner with healthcare providers around the world to provide safer, more economical
and improved care.
Pursuant to the terms of the Merger Agreement, upon completion of the acquisition,
CareFusion became a wholly-owned subsidiary of BD and each outstanding share of
common stock, par value $0.01 per share, of CareFusion (other than shares with
respect to which appraisal rights have been properly demanded and not withdrawn)
was converted into the right to receive (i) $49.00 in cash, without interest and (ii)
0.0777 of a share of common stock, par value $1.00 per share, of BD. As a result of
the completion of the acquisition, CareFusion shares will cease trading, and will be
delisted from the New York Stock Exchange.
Excluding transaction-related expenses relating to the closing, BD expects the
acquisition to have an immaterial impact on the Companys results of operations in the
second fiscal quarter, which ends on March 31, 2015. The Company will provide an
update to its fiscal year 2015 outlook on its second fiscal quarter earnings conference
call in May. Beginning in the second half of fiscal year 2015, BD will report a new
Medical segment structure, which will include CareFusion. For more detailed
information on BDs reporting changes, please refer to the BD Reporting Changes
slide presentation available on BDs website, www.bd.com/investors.
About BD
BD is a leading medical technology company that partners with customers and
stakeholders to address many of the worlds most pressing and evolving health needs.
Our innovative solutions are focused on improving medication management and
patient safety; supporting infection prevention practices; equipping surgical and
interventional procedures; improving drug delivery; aiding anesthesiology and
respiratory care; advancing cellular research and applications; enhancing the
diagnosis of infectious diseases and cancers; and supporting the management of
diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our
purpose of Helping all people live healthy lives by advancing the quality, accessibility,
safety and affordability of healthcare around the world. In 2015, BD welcomed
CareFusion and its products into the BD family of solutions. For more information on
BD, please visit www.bd.com.

Forward-Looking Statements
This release includes forward-looking statements subject to the safe harbor provisions
of the federal securities laws. These forward-looking statements include statements
regarding BDs current expectations regarding the expected benefits of the acquisition
of CareFusion, and anticipated future financial and operating performance and results.
Such expectations are based upon certain preliminary information, internal estimates,
and management assumptions, expectations, and plans, and are subject to a number
of risks and uncertainties inherent in projecting future conditions, events, and results.
Actual results could differ materially from expectations expressed in the forwardlooking statements if one or more of the underlying assumptions or expectations prove
to be inaccurate or are unrealized. Important factors that could cause actual results to
differ materially from such expectations are and will be detailed in the companys
filings with the Securities and Exchange Commission (SEC). Filings made by BD are
available when filed with the SEC on the BD web site at www.bd.com.

http://archive.thedailystar.net/newDesign/news-details.php?nid=31548
Thursday, April 10, 2008
Business

Sanofi-aventis completes merger in Bangladesh

Sanofi-aventis Bangladesh Ltd is the new entity that has been formed following the amalgamation of three leading
pharmaceutical companies -- Aventis Ltd, Fisons (Bangladesh) Ltd and Hoechst Marion Roussel Ltd, says a press
release.
The legal integration process has taken few years after the global merger between sanofi-synthalebo and Aventis in
September 2004 and finally the existing three legal entities have amalgamated as sanofi-aventis Bangladesh on
December 11, 2007.
The name of the newly amalgamated company has been registered with the Registrar of Joint Stock Companies and
Firms on January 31, 2008.
Sanofi-aventis, a leading pharmaceutical group that is present in more than 100 countries with around 11,000
scientists and more than 100,000 employees discovers, develops and distributes therapeutic solutions.
Sanofi-aventis Bangladesh contributed a total of Tk 28.4 crore to the national exchequer in the form of tax, VAT,
custom duties, etc. in 2007. Bangladesh government holds 45 percent shares in the company.

https://books.google.co.th/books?
id=4hmiH5GVNZIC&pg=PA47&lpg=PA47&dq=foreign+direct+investment+in+pharmaceutical+industry+in+
bangladesh&source=bl&ots=I2S3lKOadE&sig=Kz78eYOQ6rrHpvowLskRzUGVR2s&hl=en&sa=X&ved=0C
FQQ6AEwCGoVChMI_N7g3c6YxwIVVAWOCh042gcH#v=onepage&q=foreign%20direct%20investment
%20in%20pharmaceutical%20industry%20in%20bangladesh&f=false